Sanofi and Artificial Intelligence (AI)-driven Exscientia have announced a €250m ($271.9m) drug target research collaboration and licence option agreement.
Sanofi is poised to terminate its Auvi-Q marketing deal says PDL Biopharma, citing manufacturing issues last year which led to a complete recall of the epinephrine injection product.
Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.
Sanofi Pasteur says Mexican approval for Dengvaxia vindicates the ‘industrial risk’ it took when it invested €350m in a dengue fever vaccine plant in 2009.
MannKind says it is confident sales of its inhaled insulin product Afrezza - commercialised by Sanofi - will pick up after disappointing growth since launch.
Computational drug designer Schrödinger has entered into a five-year early drug discovery collaboration with Sanofi in which Schrödinger will provide target analysis and validation to lead identification and lead optimization for as many as ten drug discovery...
Pharma has focused investment in lower risk specialty and orphan diseases to the detriment of 80% of the population, according to Sanofi’s head of R&D who calls for regulatory convergence to help reverse the trend.
Sanofi has selected Boehringer-Ingelheim to manufacture monoclonal antibodies in an agreement that extends to the French drugmaker's partner Regeneron.
Over the next few months Sanofi and non-profit PATH are delivering the first large-scale batches of an artemisinin-based combination therapy to five African countries, which will for the first time be manufactured with semi-synthetic artesunate.
In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from Sanofi and Boehringer Ingelheim.
Sanofi has inked a deal that will see it contract manufacture immunotherapy products for Transgene using a new platform developed by the two companies.
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
in-PharmaTechnologist.com presents its latest round up of executive moves in the pharma sector, including appointments at Sanofi, Amylin, Lophius Biosciences, Lophius, Adventrx, BioSante and Medicure.
French drug maker Sanofi-Aventis continues to spearhead the fight for a more secure pharmaceutical supply chain by launching an anti-counterfeit medication initiative in Egypt.
Sanofi-Aventis says French manufacturing operations will focus on vaccine and biotech drugs, unveiling €150m ($202m) plan to shift emphasis away from synthetic chemistry-based production.
Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.
Sanofi-aventis is initiating the phased closing its manufacturing facility in Kansas, US, with complete shutdown expected to occur in 2012 and impact on 370 employees.
Sanofi-Aventis is continuing to expand in emerging markets by agreeing to acquire Indian vaccine manufacturer Shantha Biotechnics in a deal that values the company at €550m ($784m).
Sanofi-Aventis has moved to defend its long-acting diabetes treatment Lantus (insulin glargine) and says that recent research linking it to the development of cancer is of “poor quality.”
Sanofi Pasteur, the vaccines unit of French drug major Sanofi Aventis, has received a reference strain of the H1N1 swine flu virus from the US CDC and expects to complete work on an industrial “seed stock” in the next two weeks.
Sanofi Pasteur has landed what it believes will be the first of a series of orders from the US Department of Health and Human Services (HHS) to produce H1N1 vaccines.
Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I projects.
Sanofi-Aventis is investing a further $90m in its Chinese manufacturing facility and performing “the world’s largest diabetes genotyping project” in partnership with the Chinese Diabetes Society.
Sanofi-Aventis is to sell its liquid drug manufacturing plant in Colomiers, southwest France, to industry specialist Unither for an as yet undisclosed sum.
Sanofi-Aventis Canada has licensed I-many’s suite of software for managing pharmaceutical contracts, with the IT company also performing installation, maintenance and support.
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
GlaxoSmithKline’s head of North American operations, Chris Viehbacher, is to takeover as chief operating officer (CEO) at Sanofi-Aventis after he missed out on the top spot at GSK last year.
Sanofi Aventis has extended its deal with China’s NovaMed, adding the anti-convulsant Depakine (valproic acid) to the latter firm’s distribution roster.
